Related Experiment Videos
[Evaluation of the factor XIIa assay kit]
M Munakata1, Y Komiyama, T Mori
1Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, Moriguchi.
Rinsho Byori. the Japanese Journal of Clinical Pathology
|September 1, 1996
Summary
The activated Factor XII assay kit may not accurately measure complexed Factor XIIa in plasma due to significant interference from common inhibitors. This impacts hypercoagulable state detection.
Area of Science:
- Biochemistry
- Hematology
- Clinical Diagnostics
Context:
- Hypercoagulable states are increasingly detected using activated coagulation factor assays.
- Contact phase hypercoagulation detection is limited, with a novel activated factor XI and alpha 1 antitrypsin complex assay available.
- A commercial assay kit for activated Factor XII (XIIa) is now available, with reported reference ranges.
Purpose:
- To evaluate the accuracy of a commercial activated Factor XII assay kit.
- To investigate the impact of plasma inhibitors on activated Factor XII assay results.
- To determine if the assay can reliably detect complexed Factor XIIa in plasma.
Summary:
- The activated Factor XII assay kit showed significantly decreased recovery rates for purified Factor XIIa when incubated with plasma inhibitors.
- Recovery ratios were 82% for diisopropyl fluoro-phosphate (DFP)-XIIa, 63% for corn trypsin inhibitor (CTI)-XIIa, and 0% for C1 inhibitor (C1I)-XIIa.
- The assay demonstrated a low recovery (7%) for Factor XIIa without inhibitors, suggesting it does not accurately reflect complexed Factor XIIa levels.
Impact:
- The findings suggest limitations in the current activated Factor XII assay kit's ability to accurately quantify Factor XIIa in the presence of plasma inhibitors.
- This may affect the reliability of using this kit for diagnosing hypercoagulable states.
- Further research is needed to develop or validate assays that can accurately measure complexed Factor XIIa in clinical samples.